LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Search

Onconova Therapeutics Inc

Gesloten

0

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+510.69% upside

Onconova Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 jun 2026, 23:36 UTC

Winsten

Correction to Oracle Reports Higher 4Q Profit Article

10 jun 2026, 23:19 UTC

Populaire aandelen

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

10 jun 2026, 23:09 UTC

Belangrijke Marktbewegers

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

10 jun 2026, 23:04 UTC

Winsten

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

10 jun 2026, 20:44 UTC

Belangrijke Marktbewegers

Caterpillar Raises Quarterly Dividend 8%

10 jun 2026, 23:49 UTC

Acquisities, Fusies, Overnames

Elliott: Northern Star Should Take No Options Off The Table

10 jun 2026, 23:48 UTC

Acquisities, Fusies, Overnames

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

10 jun 2026, 23:48 UTC

Acquisities, Fusies, Overnames

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

10 jun 2026, 23:47 UTC

Marktinformatie

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

10 jun 2026, 23:47 UTC

Acquisities, Fusies, Overnames

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

10 jun 2026, 23:46 UTC

Acquisities, Fusies, Overnames

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

10 jun 2026, 23:38 UTC

Marktinformatie

Global Equities Roundup: Market Talk

10 jun 2026, 23:38 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

10 jun 2026, 23:38 UTC

Marktinformatie

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

10 jun 2026, 23:32 UTC

Marktinformatie

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

10 jun 2026, 23:20 UTC

Marktinformatie

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

10 jun 2026, 22:05 UTC

Marktinformatie

Correction to Bank of Canada Stays on Hold Market Talk

10 jun 2026, 21:57 UTC

Winsten

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 jun 2026, 21:52 UTC

Winsten

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 jun 2026, 21:35 UTC

Winsten

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 jun 2026, 21:22 UTC

Winsten

Oracle Stock Slides on Increased Capital Spending -- WSJ

10 jun 2026, 20:50 UTC

Marktinformatie
Winsten

Tech, Media & Telecom Roundup: Market Talk

10 jun 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

10 jun 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

10 jun 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

10 jun 2026, 20:39 UTC

Marktinformatie
Winsten

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

10 jun 2026, 20:34 UTC

Winsten

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 jun 2026, 20:33 UTC

Winsten

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

10 jun 2026, 20:33 UTC

Marktinformatie
Winsten

Global Equities Roundup: Market Talk

10 jun 2026, 20:33 UTC

Marktinformatie
Winsten

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

Peer Vergelijking

Prijswijziging

Onconova Therapeutics Inc Prognose

Koersdoel

By TipRanks

510.69% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 8 USD  510.69%

Hoogste 8 USD

Laagste 8 USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Onconova Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

1

Buy

0

Hold

0

Sell

Financieel

$

help-icon Live chat